Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Atara Biotherapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 82 | 48 | −34 |
| SharesConverted for a 1-for-25 split | 3.33M | 2.84M | −495.3K (−14.9%) |
| Value | $57.8M | $24.1M | −$33.7M (−58.3%) |
New holders (13)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Centiva Capital, LP | 140,250 | $1.19M | 0.06% |
| Qube Research & Technologies Ltd | 102,663 | $872.6K | 0.00% |
| Prudential Financial Inc | 36,340 | $308.9K | 0.00% |
| Bridgeway Capital Management, LLC | 14,000 | $119.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 9,271 | $78.8K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 6,292 | $53.5K | 0.01% |
| Mirae Asset Global ETFs Holdings Ltd. | 1,927 | $16.4K | 0.00% |
| Lazard Asset Management LLC | 308 | $2.00K | 0.00% |
| Macquarie Group Ltd | 197 | $1.68K | 0.00% |
| Catalyst Funds Management Pty Ltd | 100 | $850 | 0.00% |
| Federated Hermes, Inc. | 57 | $485 | 0.00% |
| EverSource Wealth Advisors, LLC | 35 | $344 | 0.00% |
| Russell Investments Group, Ltd. | 2 | $17 | 0.00% |
Sold out (47)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.